By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Y-mAbs Therapeutics Inc. 

750 Third Avenue, 9th Floor

New York  New York  10017  U.S.A.
Phone: 212-847-9841 Fax: n/a


YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7-H3. To further improve our bispecific antibodies, we are collaborating with MSK on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Our treatments could potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.


April 2014


Founder, President and Head of Business Development and Strategy: Thomas Gad

CEO: Claus Moller

CFO: Bo Kruse

SVP, Head of Technical Operations: Torben Lund-Hansen, PhD

SVP, CMO: Ole Baadsgaard, MD, DMSc


Please click here for YmAbs' job opportunities.

Key Statistics

Ownership: Private

Web Site: Y-mAbs


Company News